Clinical Trials
218 trialsNeckTAR-IN
Centre Jean Perrin
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
K4CARE-PDAC
Chang Gung Memorial Hospital
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
HER2 CR
Nagoya City University
ROTATE
Yale University
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
University of Nebraska
SHERLOCK
University Health Network, Toronto
PREeMPT
Medical College of Wisconsin
retroESGO ov1
European Society of Gynaecological Oncology
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
University of Aarhus
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
PREDICT-RD
UNC Lineberger Comprehensive Cancer Center
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Dartmouth-Hitchcock Medical Center
VEN+IDAC vs IDAC in AML
Guangdong Second Provincial General Hospital
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Stanford University
RT4
The Lymphoma Academic Research Organisation
PALAVY
Abramson Cancer Center at Penn Medicine
Motixafortide for MRD Sensitization in AML
Washington University School of Medicine
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Ruijin Hospital
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
DEL-MRD-CHID
Fudan University
ctDNA in Cutaneous Squamous Cell Carcinoma
Massachusetts Eye and Ear Infirmary
AlloNK1
Singapore General Hospital
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Peking University People's Hospital
CIRCALL
Assistance Publique - Hôpitaux de Paris
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
EMAT
Medical College of Wisconsin
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Second Xiangya Hospital of Central South University
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
TRACE-BTC
Aarhus University Hospital
MiRaDoR
MedSIR
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
University of Oklahoma
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Peking University People's Hospital
LAL-2025
PETHEMA Foundation
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Peking University People's Hospital
Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial
Sun Yat-sen University
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Dana-Farber Cancer Institute
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer
Asan Medical Center
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Columbia University
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
EURHOLY
Assistance Publique - Hôpitaux de Paris
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Tongji Hospital
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
UNC Lineberger Comprehensive Cancer Center